Patents Assigned to Oncoquest, Inc.
  • Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
    Patent number: 10392444
    Abstract: The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: August 27, 2019
    Assignee: Oncoquest, Inc.
    Inventors: Ragupathy Madiyalakan, Christopher F Nicodemus